Giant investment for the Novo Nordisk laboratory. For $11.5 billion, the Danish laboratory purchased Catalent.
Last week, its capitalization crossed the $500 billion mark on the stock market. The Danish laboratory is experiencing unprecedented success thanks to two drugs, Ozempic, an antidiabetic, and Wegovy, its appetite suppressant version, intended for people suffering from obesity. In 2023, the laboratory had already invested 8 billion euros in its production sites.